Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 151

1.

Transcriptome profiling identifies HMGA2 as a biomarker of melanoma progression and prognosis.

Raskin L, Fullen DR, Giordano TJ, Thomas DG, Frohm ML, Cha KB, Ahn J, Mukherjee B, Johnson TM, Gruber SB.

J Invest Dermatol. 2013 Nov;133(11):2585-92. doi: 10.1038/jid.2013.197.

2.

Association Between NRAS and BRAF Mutational Status and Melanoma-Specific Survival Among Patients With Higher-Risk Primary Melanoma.

Thomas NE, Edmiston SN, Alexander A, Groben PA, Parrish E, Kricker A, Armstrong BK, Anton-Culver H, Gruber SB, From L, Busam KJ, Hao H, Orlow I, Kanetsky PA, Luo L, Reiner AS, Paine S, Frank JS, Bramson JI, Marrett LD, Gallagher RP, Zanetti R, Rosso S, Dwyer T, Cust AE, Ollila DW, Begg CB, Berwick M, Conway K; GEM Study Group..

JAMA Oncol. 2015 Jun;1(3):359-68. Erratum in: JAMA Oncol. 2015 Jun;1(3):285.

3.

Gene expression profiling of primary cutaneous melanoma and clinical outcome.

Winnepenninckx V, Lazar V, Michiels S, Dessen P, Stas M, Alonso SR, Avril MF, Ortiz Romero PL, Robert T, Balacescu O, Eggermont AM, Lenoir G, Sarasin A, Tursz T, van den Oord JJ, Spatz A; Melanoma Group of the European Organization for Research and Treatment of Cancer..

J Natl Cancer Inst. 2006 Apr 5;98(7):472-82.

4.

Disease progression and patient survival are significantly influenced by BRAF protein expression in primary melanoma.

Safaee Ardekani G, Jafarnejad SM, Khosravi S, Martinka M, Ho V, Li G.

Br J Dermatol. 2013 Aug;169(2):320-8. doi: 10.1111/bjd.12351.

PMID:
23550516
5.

Molecular characterization of a selected cohort of patients affected by pulmonary metastases of malignant melanoma: Hints from BRAF, NRAS and EGFR evaluation.

Ulivieri A, Cardillo G, Manente L, Paone G, Mancuso AP, Vigna L, Di Stasio E, Gasbarra R, Girlando S, Leone A.

Oncotarget. 2015 Aug 14;6(23):19868-79.

6.

BRAF-V600E expression in primary nodular melanoma is associated with aggressive tumour features and reduced survival.

Hugdahl E, Kalvenes MB, Puntervoll HE, Ladstein RG, Akslen LA.

Br J Cancer. 2016 Mar 29;114(7):801-8. doi: 10.1038/bjc.2016.44.

PMID:
26924424
7.

Clinicopathological characteristics and mutation profiling in primary cutaneous melanoma.

Yaman B, Akalin T, Kandiloğlu G.

Am J Dermatopathol. 2015 May;37(5):389-97. doi: 10.1097/DAD.0000000000000241.

PMID:
25357015
8.

The role of BRAF mutations in primary melanoma growth rate and survival.

Mar VJ, Liu W, Devitt B, Wong SQ, Dobrovic A, McArthur GA, Wolfe R, Kelly JW.

Br J Dermatol. 2015 Jul;173(1):76-82. doi: 10.1111/bjd.13756.

PMID:
25752325
9.

NRAS mutation status is an independent prognostic factor in metastatic melanoma.

Jakob JA, Bassett RL Jr, Ng CS, Curry JL, Joseph RW, Alvarado GC, Rohlfs ML, Richard J, Gershenwald JE, Kim KB, Lazar AJ, Hwu P, Davies MA.

Cancer. 2012 Aug 15;118(16):4014-23. doi: 10.1002/cncr.26724.

10.

Increased levels of β-catenin, LEF-1, and HPA-1 correlate with poor prognosis for acral melanoma with negative BRAF and NRAS mutation in BRAF exons 11 and 15 and NRAS exons 1 and 2.

Xu S, Yang Z, Zhang J, Jiang Y, Chen Y, Li H, Liu X, Xu D, Chen Y, Yang Y, Zhang Y, Li D, Xia J.

DNA Cell Biol. 2015 Jan;34(1):69-77. doi: 10.1089/dna.2014.2590.

11.

Correlation of somatic mutations and clinical outcome in melanoma patients treated with Carboplatin, Paclitaxel, and sorafenib.

Wilson MA, Zhao F, Letrero R, D'Andrea K, Rimm DL, Kirkwood JM, Kluger HM, Lee SJ, Schuchter LM, Flaherty KT, Nathanson KL.

Clin Cancer Res. 2014 Jun 15;20(12):3328-37. doi: 10.1158/1078-0432.CCR-14-0093.

12.

Association of galectin-3 expression with melanoma progression and prognosis.

Brown ER, Doig T, Anderson N, Brenn T, Doherty V, Xu Y, Bartlett JM, Smyth JF, Melton DW.

Eur J Cancer. 2012 Apr;48(6):865-74. doi: 10.1016/j.ejca.2011.09.003.

PMID:
22071132
13.

TERT promoter mutations in melanoma survival.

Nagore E, Heidenreich B, Rachakonda S, Garcia-Casado Z, Requena C, Soriano V, Frank C, Traves V, Quecedo E, Sanjuan-Gimenez J, Hemminki K, Landi MT, Kumar R.

Int J Cancer. 2016 Jul 1;139(1):75-84. doi: 10.1002/ijc.30042.

PMID:
26875008
14.

Prognostic value of BRAF(V⁶⁰⁰) mutations in melanoma patients after resection of metastatic lymph nodes.

Moreau S, Saiag P, Aegerter P, Bosset D, Longvert C, Hélias-Rodzewicz Z, Marin C, Peschaud F, Chagnon S, Zimmermann U, Clerici T, Emile JF.

Ann Surg Oncol. 2012 Dec;19(13):4314-21. doi: 10.1245/s10434-012-2457-5.

PMID:
22772867
15.

Overexpression of HMGA2 promotes metastasis and impacts survival of colorectal cancers.

Wang X, Liu X, Li AY, Chen L, Lai L, Lin HH, Hu S, Yao L, Peng J, Loera S, Xue L, Zhou B, Zhou L, Zheng S, Chu P, Zhang S, Ann DK, Yen Y.

Clin Cancer Res. 2011 Apr 15;17(8):2570-80. doi: 10.1158/1078-0432.CCR-10-2542.

16.

The role of CCND1 alterations during the progression of cutaneous malignant melanoma.

Vízkeleti L, Ecsedi S, Rákosy Z, Orosz A, Lázár V, Emri G, Koroknai V, Kiss T, Ádány R, Balázs M.

Tumour Biol. 2012 Dec;33(6):2189-99. doi: 10.1007/s13277-012-0480-6.

PMID:
23001925
17.

BRAF/NRAS mutation frequencies among primary tumors and metastases in patients with melanoma.

Colombino M, Capone M, Lissia A, Cossu A, Rubino C, De Giorgi V, Massi D, Fonsatti E, Staibano S, Nappi O, Pagani E, Casula M, Manca A, Sini M, Franco R, Botti G, Caracò C, Mozzillo N, Ascierto PA, Palmieri G.

J Clin Oncol. 2012 Jul 10;30(20):2522-9. doi: 10.1200/JCO.2011.41.2452.

PMID:
22614978
18.

Metastatic melanoma of unknown primary resembles the genotype of cutaneous melanomas.

Egberts F, Bergner I, Krüger S, Haag J, Behrens HM, Hauschild A, Röcken C.

Ann Oncol. 2014 Jan;25(1):246-50. doi: 10.1093/annonc/mdt411.

19.

Prognostic and clinicopathologic associations of oncogenic BRAF in metastatic melanoma.

Long GV, Menzies AM, Nagrial AM, Haydu LE, Hamilton AL, Mann GJ, Hughes TM, Thompson JF, Scolyer RA, Kefford RF.

J Clin Oncol. 2011 Apr 1;29(10):1239-46. doi: 10.1200/JCO.2010.32.4327.

PMID:
21343559
20.

Stage-specific prognostic biomarkers in melanoma.

Cheng Y, Lu J, Chen G, Ardekani GS, Rotte A, Martinka M, Xu X, McElwee KJ, Zhang G, Zhou Y.

Oncotarget. 2015 Feb 28;6(6):4180-9.

Items per page

Supplemental Content

Support Center